Nimodipine in treatment of bipolar disorder

Romanov D.V.; Sheyanov A.M.; Samsonova M.D.; Yuzbashyan P.G.

doi:https://doi.org/10.17116/jnevro202312312120

Close metadata

Recommended articles:

The gut microbiota in bipolar disorder. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):28-33

Clinical and psychopathological features of treatment-resistant schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):43-50

Comparative study of cognitive impairment in subgroups of bipolar affective disorder types I and II, occurring with and without psychotic symptoms. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):7-11

Association of cortisol levels with psychopathological features of depression and therapeutic response in female patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):45-54

Analysis of Russian studies of suicidal behavior in patients with bipolar affective disorder. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):25-33

Glucocorticoid-resistant forms of endocrine ophthalmopathy. Russian Annals of Ophthalmology. 2024;(6):125-130

Genome instability of the cholera agent: role in the evolution of pathogenicity, drug resistance and adaptation to a changing environment. Molecular Genetics, Microbiology and Virology. 2025;(2):3-13

Abstract:

The purpose of this review is to correlate current data on the molecular mechanisms of action of the drug Nimodipine with its clinical effects and applicability in mental disorders belonging to the spectrum of affective pathology. The article discusses the prospects for using the calcium channel blocker nimodipine as a method of both mono and combination therapy for bipolar disorders with various types of course. Nimodipine is a selective blocker of voltage-dependent calcium channels, a dihydropyridine derivative. By blocking L type calcium channels, it prevents the entry of calcium ions into the cell. Due to its pronounced ability to penetrate the blood-brain barrier, it has a selective effect on brain neurons and has a vasodilating, antihypertensive and normotimic effect. Nimodipine blocks LTCC channels in brain neurons, thereby influencing synaptic plasticity, transmitter release and excitation-transcription coupling, which makes it possible to influence various clinical conditions with pathology in the area of affect, including bipolar disorders with ultra-rapid cycling, and also, in cases with high resistance and intolerance to other mood stabilizers.

Keywords:

bipolar affective disorder

nimodipine

calcium antagonists

CACNA1C

LTCC

ultra-rapid cycling

continuous circular course

resistance

tolerance

Authors:

Romanov D.V.

Sechenov First Moscow State Medical University (Sechenov University);
Mental Health Research Center

ORCID: 0000-0002-1822-8973

Sheyanov A.M.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0009-0009-9601-0193

Samsonova M.D.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0003-2558-2732

Yuzbashyan P.G.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0002-7441-5546

Received:

01.11.2023

Accepted:

03.11.2023

Close metadata

References:

International Classification of Diseases, Eleventh Revision (ICD-11), World Health Organization (WHO) 2019/2021. https://icd.who.int/browse11
Falret J. De la folie circulaire ou forme de maladie mentale caracterisée par alternative régulière de la manie et de la melancholie. 1851.
Baillarger JGF. Note sur un genre de folie dont les accè s sont caracté risé s par deux pé riodes réguliè res, l’une de dépression et l’autre d’excitation. Bull Acad Imperiale Med. Séance 31st January 1854.
Kraepelin, E. Manic-depressive Insanity and Paranoia. Translated by R. Mary Barclay from the Eighth German Edition of the «Textbook of Psychiatry», vol. 3 and 4, 1920. New York: Arno Press; 1976.
Swartz HA, Suppes T, American Psychiatric Association Publishing, eds. Bipolar II Disorder: Recognition, Understanding, and Treatment. First edition. American Psychiatric Association Publishing; 2019.
Kukopulos A, Reginaldi D, Laddomada P, et al. Course of the Manic-Depressive Cycle and Changes Caused by Treatments. Pharmacopsychiatry. 2008;13(04):156-167. https://doi.org/10.1055/s-2007-1019628
Haag H, Heidorn A, Haag M, Greil W. Sequence of affective polarity and lithium response: Preliminary report on munich sample. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 1987;11(2-3):205-208. https://doi.org/10.1016/0278-5846(87)90061-3
Dunner DL, Patrick V, Fieve RR. Rapid cycling manic depressive patients. Comprehensive Psychiatry. 1977;18(6):561-566. https://doi.org/10.1016/S0010-440X(97)90006-7
Wittenborn JR. Deductive Approaches To The Catecholamine Hypothesis Of Affective Disorders. The Journal of Nervous and Mental Disease. 1974;158(5):320-324. https://doi.org/10.1097/00005053-197405000-00002
Tissot R. The Common Pathophysiology of Monoaminergic Psychoses: a New Hypothesis. Neuropsychobiology. 1975;1(4):243-260. https://doi.org/10.1159/000117498
Stockmeier CA. Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. Journal of Psychiatric Research. 2003;37(5):357-373. https://doi.org/10.1016/S0022-3956(03)00050-5
Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 1st ed. Cambridge University Press; 2022. https://doi.org/10.1017/9781009053365
Jimerson DC, Post RM, Carman JS, et al. CSF calcium: clinical correlates in affective illness and schizophrenia. Biol Psychiatry. 1979;14(1):37-51.
Willow M, Kuenzel EA, Catterall WA. Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol Pharmacol. 1984;25(2):228-234.
Maan JS, Duong T vi H, Saadabadi A. Carbamazepine. In: StatPearls. StatPearls Publishing; 2023. Accessed October 26, 2023. https://www.ncbi.nlm.nih.gov/books/NBK482455/
Casamassima F, Hay AC, Benedetti A, et al. L‐type calcium channels and psychiatric disorders: A brief review. American J of Med Genetics Pt B. 2010;153B(8):1373-1390. https://doi.org/10.1002/ajmg.b.31122
Gareri P, Mattace R, Nava F, De Sarro G. Role of calcium in brain aging. General Pharmacology: The Vascular System. 1995;26(8):1651-1657. https://doi.org/10.1016/0306-3623(95)00043-7
Crammer JL. Calcium metabolism and mental disorder. Psychol Med. 1977;7(4):557-560. https://doi.org/10.1017/S003329170000619X
Carman JS, Wyatt RJ. Calcium: bivalent cation in the bivalent psychoses. Biol Psychiatry. 1979;14(2):295-336.
Dubovsky SL. Increased Platelet Intracellular Calcium Concentration in Patients With Bipolar Affective Disorders. Arch Gen Psychiatry. 1989;46(7):632. https://doi.org/10.1001/archpsyc.1989.01810070058010
Harrison PJ, Hall N, Mould A, Al-Juffali N, Tunbridge EM. Cellular calcium in bipolar disorder: systematic review and meta-analysis. Mol Psychiatry. 2021;26(8):4106-4116. https://doi.org/10.1038/s41380-019-0622-y
Nowycky MC, Fox AP, Tsien RW. Three types of neuronal calcium channel with different calcium agonist sensitivity. Nature. 1985;316(6027):440-443. https://doi.org/10.1038/316440a0
Little HJ. L-Type Calcium Channel Blockers: A Potential Novel Therapeutic Approach to Drug Dependence. Pharmacol Rev. 2021;73(4):127-154. https://doi.org/10.1124/pharmrev.120.000245
Herold KG, Hussey JW, Dick IE. CACNA1C-Related Channelopathies. In: Striessnig J, ed. Voltage-Gated Ca2+ Channels: Pharmacology, Modulation and Their Role in Human Disease. Vol 279. Handbook of Experimental Pharmacology. Springer International Publishing; 2023;159-181. https://doi.org/10.1007/164_2022_624
Kabir ZD, Lee AS, Rajadhyaksha AM. L‐type Ca 2+ channels in mood, cognition and addiction: integrating human and rodent studies with a focus on behavioural endophenotypes. The Journal of Physiology. 2016;594(20):5823-5837. https://doi.org/10.1113/JP270673
Hardingham GE, Chawla S, Johnson CM, Bading H. Distinct functions of nuclear and cytoplasmic calcium in the control of gene expression. Nature. 1997;385(6613):260-265. https://doi.org/10.1038/385260a0
Striessnig J, Koschak A, Sinnegger-Brauns MJ, et al. Role of voltage-gated L-type Ca2+ channel isoforms for brain function. Biochemical Society Transactions. 2006;34(5):903-909. https://doi.org/10.1042/BST0340903
Schlecker C, Boehmerle W, Jeromin A, et al. Neuronal calcium sensor-1 enhancement of InsP3 receptor activity is inhibited by therapeutic levels of lithium. J Clin Invest. 2006;116(6):1668-1674. https://doi.org/10.1172/JCI22466
Foskett JK, White C, Cheung KH, Mak DOD. Inositol Trisphosphate Receptor Ca 2+ Release Channels. Physiological Reviews. 2007;87(2):593-658. https://doi.org/10.1152/physrev.00035.2006
Scriabine A, Van Den Kerckhoff W. Pharmacology of Nimodipine: A Review. Annals of the New York Academy of Sciences. 1988;522(1):698-706. https://doi.org/10.1111/j.1749-6632.1988.tb33415.x
Goodnick PJ. The use of nimodipine in the treatment of mood disorders: Nimodipine in mood disorders. Bipolar Disorders. 2000;2(3):165-173. https://doi.org/10.1034/j.1399-5618.2000.020303.x
Caro A, Tarabova B, Rojo-Ruiz J, Lacinova L. Nimodipine inhibits AP firing in cultured hippocampal neurons predominantly due to block of voltage-dependent potassium channels. Gen Physiol Biophys. 2011;30(05):44-53. https://doi.org/10.4149/gpb_2011_SI1_44
Pazzaglia PJ, Post RM, Ketter TA, et al. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Research. 1993;49(3):257-272. https://doi.org/10.1016/0165-1781(93)90066-P
Pazzaglia PJ, Post RM, Ketter TA, et al. Nimodipine Monotherapy and Carbamazepine Augmentation in Patients With Refractory Recurrent Affective Illness: Journal of Clinical Psychopharmacology. 1998;18(5):404-413. https://doi.org/10.1097/00004714-199810000-00009
Goodnick PJ. Nimodipine treatment of rapid cycling bipolar disorder. J Clin Psychiatry. 1995;56(7):330.
Brunet G, Cerlich B, Robert P, et al. Open Trial of a Calcium Antagonist, Nimodipine, in Acute Mania: Clinical Neuropharmacology. 1990;13(3):224-228. https://doi.org/10.1097/00002826-199006000-00004
Hesslinger B, Riedel H, Hellwig B, et al. Phase prevention in bipolar affective disorder with nimodipine. A case report. Nervenarzt. 1996;67(5):394-396.
Manna V. Bipolar affective disorders and role of intraneuronal calcium. Therapeutic effects of the treatment with lithium salts and/or calcium antagonist in patients with rapid polar inversion. Minerva Med. 1991;82(11):757-763.
Davanzo PA, Krah N, Kleiner J, McCracken J. Nimodipine Treatment of an Adolescent with Ultradian Cycling Bipolar Affective Illness. Journal of Child and Adolescent Psychopharmacology. 1999;9(1):51-61. https://doi.org/10.1089/cap.1999.9.51
Mallinger AG, Thase ME, Haskett R, et al. Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms. Bipolar Disorders. 2008;10(8):856-866. https://doi.org/10.1111/j.1399-5618.2008.00636.x
Price WA, Shalley JE. Lithium‐Verapamil Toxicity in the Elderly. J American Geriatrics Society. 1987;35(2):177-178. https://doi.org/10.1111/j.1532-5415.1987.tb01353.x
Helmuth D, Ljaljevic Z, Ramirez L, Meltzer HY. Choreoathetosis induced by verapamil and lithium treatment. J Clin Psychopharmacol. 1989;9(6):454-455.
Dubovsky SL, Franks RD, Allen S. Verapamil: a new antimanic drug with potential interactions with lithium. J Clin Psychiatry. 1987;48(9):371-372.
Price WA, Giannini AJ. Neurotoxicity Caused by Lithium‐Verapamil Synergism. The Journal of Clinical Pharma. 1986;26(8):717-719. https://doi.org/10.1002/j.1552-4604.1986.tb02980.x
Cipriani A, Saunders K, Attenburrow MJ, et al. A systematic review of calcium channel antagonists in bipolar disorder and some considerations for their future development. Mol Psychiatry. 2016;21(10):1324-1332. https://doi.org/10.1038/mp.2016.86
Caillard V. Treatment of Mania Using a Calcium Antagonist — Preliminary Trial. Neuropsychobiology. 1985;14(1):23-26. https://doi.org/10.1159/000118196
Dose M, Emrich HM, Cording-Tömmel C, Von Zerssen D. Use of calcium antagonists in mania. Psychoneuroendocrinology. 1986;11(2):241-243. https://doi.org/10.1016/0306-4530(86)90060-0
Silverstone PH, Birkett L. Diltiazem as augmentation therapy in patients with treatment-resistant bipolar disorder: a retrospective study. J Psychiatry Neurosci. 2000;25(3):276-280.
Ostacher MJ, Iosifescu DV, Hay A, et al. Pilot investigation of isradipine in the treatment of bipolar depression motivated by genome‐wide association. Bipolar Disorders. 2014;16(2):199-203. https://doi.org/10.1111/bdi.12143
Taragano FE, Allegri R, Vicario A, et al. A double blind, randomized clinical trial assessing the efficacy and safety of augmenting standard antidepressant therapy with nimodipine in the treatment of ?vascular depression? Int J Geriat Psychiatry. 2001;16(3):254-260. https://doi.org/10.1002/gps.340
Liu J, Sun C, Wang Y, et al. Efficacy of nimodipine in the treatment of subarachnoid hemorrhage: a meta-analysis. Arq Neuropsiquiatr. 2022;80(07):663-670. https://doi.org/10.1055/s-0042-1755301
Rossiiskoe obshchestvo psikhiatrov «Klinicheskie rekomendatsii Bipolyarnoe affektivnoe rasstroistvo» 2022. (In Russ.).